Is the price fair?
What ILMN's price assumes
Illumina, Inc. trades at 42.0× earnings against 35.3× for the median Diagnostics & Research name, more expensive than its own group.
42.0
Trailing P/E · Diagnostics & Research median 35.3 · 1.19× the median: the market pays up for this one
- Price / sales
- 4.13
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.8%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +9.3%
Growth the price implies · The price pays for +9.3% free cash flow growth a year for a decade; revenue has grown +0.24% a year over the last three.
Details›
- Price / book2026-Q1
- 6.77
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $931M
- Market capitalisation
- $24.5B
- 3-year revenue growth
- +0.24%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 25.0× today against a 52.2× median |
| 52-week range | $91.00 – $225.01 |
| Today | $224.91 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #21 of 29 by Smart Score